BRIEF-EMA's CHMP Recommends Against Sanofi's Rezurock

Reuters
Oct 17
BRIEF-EMA's CHMP Recommends Against <a href="https://laohu8.com/S/GCVRZ">Sanofi</a>'s Rezurock

Oct 17 (Reuters) - EMA's CHMP:

  • EMA'S CHMP: ADOPTED POSITIVE OPINION FOR WAYRILZ FOR TREATMENT OF IMMUNE THROMBOCYTOPENIA IN ADULT PATIENTS WHO ARE REFRACTORY TO OTHER TREATMENTS

  • EMA'S CHMP: RECOMMENDED GRANTING A MARKETING AUTHORISATION FOR BRINSUPRI

  • EMA'S CHMP: RECOMMENDED NOT GRANTING MARKETING AUTHORISATION FOR REZUROCK FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE

  • EMA'S CHMP: WITHDRAWS INITIAL MARKETING APPLICATION FOR HYDROCORTISONE AGUETTANT

  • EMA'S CHMP: ADOPTED NEW SUBCUTANEOUS ROUTE OF ADMINISTRATION FOR SAPHNELO, AN ADD-ON TREATMENT IN ADULTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

  • EMA'S CHMP: CONFIRMED ITS INITIAL RECOMMENDATION TO NOT CONSIDER DEUTETRABENAZINE

  • EMA'S CHMP: POSITIVE RECOMMENDATIONS ON EXTENSIONS OF THERAPEUTIC INDICATIONS FOR BREYANZI

  • EMA'S CHMP: POSITIVE RECOMMENDATIONS ON EXTENSIONS OF THERAPEUTIC INDICATIONS FOR TREMFYA

  • EMA'S CHMP: CONFIRMS INITIAL RECOMMENDATION TO NOT CONSIDER DEUTETRABENAZINE AS NEW ACTIVE SUBSTANCE

  • EMA'S CHMP: POSITIVE RECOMMENDATIONS ON EXTENSIONS OF THERAPEUTIC INDICATIONS FOR PAXLOVID

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10